STOCKHOLM, May 26 /PRNewswire/ -- Sidec announces that the application form for the 2008 Protein Tomography(TM) Award is now available at Sidec's homepage. The winning application will be offered a Protein Tomography(TM) study in collaboration with Sidec. A Protein Tomography(TM) study is typically in the range of 0.1 and 0.5 million Euro and will be funded by Sidec.
The Protein Tomography(TM) Award 2008 is given to acknowledge innovative project ideas in the areas of protein therapeutics and antibody drug development.
A committee chaired by Sidec's CSO Dr. Anders Aberg will select the
winning Protein Tomography(TM) project according to the following criteria:
- Biological question of scientific significance and/or commercial
- Strategically important for the applying company
- With the aim to be published at a time mutually agreed upon
- Technically suitable for Protein Tomography(TM)
Only research groups in the biopharmaceutical industry who have not yet worked with Sidec are eligible for the Award to get acquainted with Protein Tomography(TM).
Please visit http://www.sidec.com to apply. Deadline for Application is July 31, 2008
"I had an excellent experience collaborating with Sidec and utilizing their Protein Tomography(TM) technology. I welcome this Award as a positive step to expose research groups in the biopharmaceutical industry to this revolutionary technology. At UCB we used Protein Tomography(TM) to image the synaptic vesicle of protein 2A in situ. To my knowledge this is the only method available today where it is possible to visualize 3-D images of individual molecules in situ," says Berkley Lynch, previously Principal Investigator at UCB.
About Sidec AB:
Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec offers collaborative research projects to the biopharmaceutical industry that reveal unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope.
|SOURCE Sidec AB|
Copyright©2008 PR Newswire.
All rights reserved